Spero Therapeutics, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Dec 2014 | — | $-6.1M | $256.0K |
| Dec 2015 | — | $-18.6M | $5.7M |
| Sep 2016 | — | — | $11.3M |
| Dec 2016 | — | $-45.4M | $10.3M |
| Mar 2017 | — | — | $46.4M |
| Sep 2017 | — | $-82.2M | $25.4M |
| Dec 2017 | — | $84.6M | $87.3M |
| Mar 2018 | — | $74.5M | $52.6M |
| Jun 2018 | — | $65.3M | $48.7M |
| Sep 2018 | — | $125.2M | $40.5M |
| Dec 2018 | — | $115.5M | $34.1M |
| Mar 2019 | — | $113.0M | $49.4M |
| Jun 2019 | — | $109.3M | $71.1M |
| Sep 2019 | — | $92.7M | $45.6M |
| Dec 2019 | — | $74.6M | $29.7M |
| Mar 2020 | — | $82.4M | $64.4M |
| Jun 2020 | — | $73.7M | $65.3M |
| Sep 2020 | — | $132.8M | $125.2M |
| Dec 2020 | — | $132.0M | $85.2M |
| Mar 2021 | — | $118.8M | $77.0M |
| Jun 2021 | — | $90.3M | $71.6M |
| Sep 2021 | — | $111.9M | $112.9M |
| Dec 2021 | — | $88.3M | $112.6M |
| Mar 2022 | — | $62.5M | $72.1M |
| Jun 2022 | — | $35.9M | $45.4M |
| Sep 2022 | — | $32.5M | $50.4M |
| Dec 2022 | — | $75.9M | $109.1M |
| Mar 2023 | — | $64.8M | $96.3M |
| Jun 2023 | — | $54.8M | $77.7M |
| Sep 2023 | — | $53.7M | $93.8M |
| Dec 2023 | — | $106.9M | $76.3M |
| Mar 2024 | — | $96.2M | $82.3M |
| Jun 2024 | — | $80.5M | $63.5M |
| Sep 2024 | — | $65.5M | $76.3M |
| Dec 2024 | — | $46.1M | $52.9M |
| Mar 2025 | — | $33.8M | $48.9M |
| Jun 2025 | — | $32.8M | $31.2M |
| Sep 2025 | — | $26.5M | $48.6M |
| Dec 2025 | — | $59.0M | $40.3M |
| Mar 2026 | — | $52.9M | $56.1M |
| Jun 2026 | — | $44.2M | $50.8M |